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EDITORIAL REVIEW
Complications of total parenteral nutrition
Continued technological improvements in the quality of nu-
tritional formulations and techniques for parenteral administra-
tion have resulted in a major improvement in patient care. The
ability to provide all necessary nutrients by intravenous infu-
sion, so-called total parenteral nutrition (TPN), has sustained
life and growth in patients who otherwise would have died.
Most adult patients who derive benefit from this procedure are
those with disorders in which alimentary dysfunction precludes
adequate nutrition to either save life or prevent serious disease.
Included among these disorders are various forms of carcinoma
of the gastrointestinal tract, esophageal stricture or stenosis,
intestinal fistulae, severe pancreatitis, and the "short-bowel"
syndrome. Perhaps one of its advantages has been to re-
establish adequate nutritional vitality to patients who suffered
life-threatening malnutrition and weight loss and who, following
TPN, could undergo corrective surgical procedures.
The purpose of this editorial review is to discuss several
interesting and sometimes preventable complications that result
from the use of TPN and, in addition, to point out several
situations in which TPN used too enthusiastically might directly
result in death. This will not be a comprehensive review of all
complications one may encounter in patients undergoing TPN.
Rather, emphasis will be placed on certain electrolyte distur-
bances, with special emphasis on phosphate deficiency and its
resulting problems. Although infection, oxalosis, disturbances
of carbohydrate and lipid metabolism and the potentially im-
portant disorders related to carnitine deficiency are of critical
importance in patients undergoing TPN, they will not be
reviewed in this editorial.
The history of TPN has amusing as well as interesting facets.
About 300 years ago, Sir Christopher Wren administered a
mixture of ale, opium, and beer intravenously to animals. His
intravenous set was a pig bladder and his needle was a quill
from a feather [11. His work may have unintentionally rep-
resented the pioneer effort in intravenous substance abuse.
More seriously, it appears that the advent of modern TPN
therapy began (luring World War II. A fascinating review
describing treatment of starvation based on sound physiological
and biochemical principles appeared in 1945 [2]. Participants at
this conference detailed a number of interesting observations on
prisoners of war subjected to protracted starvation. They
pointed out that under such conditions, the bowel underwent
atrophy to the extent that it seemed to consist of only its serous
coat. This was probably the derivation of the term "cellophane
bowel" applied to this condition in the modern literature. Those
investigators recognized clearly that under such conditions the
intestine would not tolerate food administered by mouth. Al-
most any food acted as an irritant, causing diarrhea and
dehydration. They correctly assumed and showed that admin-
istration of nutrients intravenously for several days would
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apparently permit sufficient functional reconstitution of the
gut so that oral administration of food could be tolerated.
Our current knowledge that intestinal mucosal cells can
repopulate themselves very rapidly corresponds to those earlier
observations.
Studies conducted in 1913 by Henriques and Anderson [3]
demonstrated that nitrogen equilibrium could be achieved by
administering hydrolysates prepared from pancreatic extracts
of goat muscle. Before the end of World War II, hydrolysates of
known amino acid composition were prepared from proteins
digested in proteolytic enzymes derived from pork pancreas,
papain, or by simple hydrolysis in sulphuric acid [4]. It was
clearly recognized at that time that the drawback of sulphuric
acid hydrolysis was its destruction of tryptophane. Amino acid
solutions prepared by these techniques were successfully ad-
ministered to many starved people. The most successful tech-
nique appeared to be intravenous administration of protein
hydrolysate preparations for 1 to 3 days followed by oral
ingestion of small quantities of a solution prepared from dried
milk powder, glucose, and vitamins [5, 6]. Interest in TPN was
rekindled in 1968 when Dudrick, Wilmore, Vars, and Rhoads
[7] showed that by this technique, normal growth and develop-
ment could be maintained in children for long periods of time.
Role of TPN in acute renal failure
Germane to the interests of this Journal's readers are the
questions of whether or not TPN decreases morbidity or
whether TPN accelerates recovery of renal function in patients
with established acute renal failure. In such patients, especially
those in whom acute renal failure resulted from trauma, sepsis
or serious systemic disease, catabolism may be pronounced.
Indeed, although great advances have been made in techniques
of hemodialysis and other measures such as antibiotic therapy,
mortality associated with post-traumatic acute renal failure has
not changed appreciably since the experience of the Korean
War. There is an old principle claiming that catabolism is
inevitable in such patients. Accordingly, a person so inflicted
should be expected to lose 0.5 kg of body weight per day during
the period of oliguria. Thus, any measures that could counteract
this "inevitable" catabolic state would be useful in the man-
agement of patients with acute renal failure. In an affirmative
response to the first question, a number of investigators [8—12]
showed that restricted quantities of high quality protein admin-
istered with large amounts of nonprotein calories could reduce
net urea production, indicating that protein economy could be
Received for publication October 24, 1984
© 1985 by the International Society of Nephrology
490 Knochel
improved in such patients. The administration of such diets in
conjunction with appropriate quantities of water and electro-
lytes not only reduced the usual rate at which azotemia pro-
gressed, it also reduced the intensity of acidosis and
hyperkalemia, but, of great importance, it reduced the inanition
otherwise expected. Nevertheless, similar to some patients
with cancer [13], the salutory effects of TPN may be limited
greatly in some patients who are desperately ill and markedly
catabolic.
The evidence for claims that TPN accelerates recovery from
acute renal failure is much more tenuous. Abel et al [14] and
Abel [15] were the first to suggest that TPN improved survival
and accelerated recovery of renal function in patients with
acute renal failure. They compared one patient group who
received a solution containing both 50% glucose and essential
amino acids to another who received only 50% glucose. Provi-
sion of amino acids enhanced survival from 44 to 75%. This
work has been criticized by Wesson, Mitch, and Wilmore [16]
who pointed out that the patients studied were selected with
bias because they represented only 53 of 150 referred for TPN.
The others were excluded because of pre-existing renal failure,
renal trauma, renal arterial emboli, or because of shock or
sepsis.
In another study, Baek et al [171 reported significantly
improved survival in 129 patients by the use of a fibrin hydrolys-
ate in addition to glucose infusions. On the other hand, Freund,
Harmian, and Fischer [18] described a mortality rate of 91% in
22 patients who received a mixture of essential and nonessential
amino acids plus 50% glucose, which are results directly
opposite from those of the other investigators. Leonard, Luke,
and Siegel [191 and Soflo and Nicora [20] also failed to confirm
the salutory effects of essential amino acid administration to
patients with acute renal failure.
Feinstein et al [211 studied 30 critically ill patients with acute
renal failure who required TPN. Seven received hypertonic
glucose, 11 received glucose plus 21 g per day of essential
amino acids and 12 received glucose plus 21 g of essential and
21 g of nonessential amino acids per day. Between these three
groups, although urea production was less, neither survival nor
time of resolution of acute renal failure was significantly dif-
ferent. Wesson, Mitch, and Wilmore [16] summarized the
results of all of these studies in detail and conclude that amino
acid infusion usually results in a decrease in net urea production
but no consistent improvement in the rate of recovery of renal
function, at least as assessed by creatinine clearance. Although
there is a suggestion that survival of the episode of acute renal
failure is improved by such treatment, overall hospital survival
is not affected. Despite improvement in nutritional status, such
patients continue to die from infection or the nonrenal compli-
cations of the condition that caused acute renal failure initially.
Although common sense tells us that providing optimal
nutrition for such patients is undoubtedly good, sometimes the
associated trauma and tissue destruction are so overwhelming
that TPN may not enhance survival. There are also instances of
acute renal failure in which TPN may not be necessary, or even
justifiable, in terms of expense or potential complications: for
example, patients who have incurred acute renal failure as a
result of a transfusion reaction and may require no more than
simple conservative management.
Mineral and electrolyte disturbances of TPN
Hypokalemia. Hypokalemia occurs commonly in patients
undergoing TPN. It does not necessarily reflect potassium
deficiency. Thus, TPN solutions contain large amounts of
glucose and amino acids that both stimulate release of insulin,
or alternatively, crystalline insulin is commonly added to TPN
solutions [22]. The mechanism whereby insulin induces
hypokalemia is not clearly understood. However, Moore [23]
has published observations suggesting that insulin increases
sodium permeability of skeletal muscle cells and presumably
other tissues, and in turn, the increased sodium concentration
in the cytosol activates the magnesium-dependent, Na, K-
ATPase. As sodium is thus transported from the cell,
electronegativity is generated which in turn promotes the in-
ward movement of potassium ions from the extracellular fluid.
Other influences commonly observed in acutely ill patients
undergoing TPN could also be responsible for hypokalemia in
the absence of total body potassium depletion. For example,
hyperventilation with respiratory alkalosis also promotes the
cellular uptake of potassium ions. Evidence obtained in vitro
suggests that reduction of intracellular hydrogen ion concentra-
tion (increased pH) reduces passive outward permeability of
potassium ions without producing a comparable reduction on
the passive inward permeability [24]. The net effect is the
translocation of potassium from extracellular to intracellular
fluid. It has also been observed that catecholamine levels may
be elevated in patients who are acutely ill. Administration of
epinephrine or certain synthetic f3-adrenergic agonists, es-
pecially those with a selective effect on /3-2 adrenergic recep-
tors, promote cellular uptake of potassium ions in muscle and
liver [25]. This process appears to depend on increasing the
inward sodium leak, cyclic AMP activation, increased Na,K
ATPase activity, increased negativity of the membrane poten-
tial and passive inward movement of potassium ions. This
process can be attenuated by either nonselective f3-blockers
[26] or increased a-adrenergic activity [27].
Potassium requirements in a normal adult are approximately
0.35 to 0.5 mEq K/kg body wt/day. Requirements may increase
to 0.75 to 1.0 mEq/kg body wt during rapid accretion of muscle
tissue. To maintain normal tissue composition, about 2.5 to 3.0
mEq of K will be retained for each gram of nitrogen formed as
protein. In patients who demonstrate a sharp anabolic response
to TPN, potassium deficiency may develop as a result of
protoplasm synthesis that outstrips the availability of potassium
ions. This response tends to occur several days to 2 weeks or
more after TPN has been initiated. More immediate causes of
potassium deficiency include diarrhea or losses into the urine.
Accelerated renal excretion of potassium ions could occur in
patients who also have metabolic alkalosis as the result of loss
of gastric contents, or in patients receiving steroids or diuretics.
The glycosuria that occurs in patients undergoing TPN is
commonly of sufficient magnitude to induce loss of potassium
into the urine.
Hypomagnesemia. Normal persons require 0.3 to 0.35 mEq
of magnesium/kg/day to maintain a positive magnesium bal-
ance. Balance studies in patients on TPN indicate that about 0.5
mEq of magnesium is retained for each gram of nitrogen. These
values indicate that magnesium requirements are substantial in
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such patients and in most cases explain the development of
hypomagnesemia during a course of TPN.
In patients with serious gastrointestinal disease, especially if
complicated by steatorrhea, magnesium deficiency often exists
before initiation of TPN. The mechanisms of magnesium
malabsorption, factors promoting renal loss of magnesium and
the fact that magnesium deficiency can cause serious
hypocalcemia, potassium deficiency, and phosphorus defi-
ciency are well known. Magnesium deficiency has been impli-
cated as a cause of hypokalemia that resists correction by
potassium supplements [28] or hypocalcemia that is not ex-
plained by hypoalbuminemia [291. A patient receiving TPN who
becomes weak, who develops myoclonus, muscular fascicula-
tions, athetosis or frank tetany, should be considered to be
magnesium deficient until proven otherwise. In patients who
have become hypokalemic and hypocalcemic as a result of
magnesium deficiency, the extent of magnesium deficiency is
usually in excess of 250 or 300 mEq [301. Slight or modest
degrees of hypomagnesemia may occur with deficits as small as
30 to 100 mEq. Slight or modest degrees of hypomagnesemia
may also occur in the absence of magnesium deficiency. Studies
by Flink et al [31] suggest that in some of these cases,
hypomagnesemia may be spurious, reflecting in vitro precipita-
tion of magnesium-fatty acid salt as a result of the fatty acid
mobilization induced by high levels of catecholamines. Experi-
mentally, it has been shown that administration of catechola-
mines causes a reduction of serum magnesium concentrations
[32]. Studies of Flink et al [31] showed that administration of
nicotinamide prevented mobilization of fatty acids in response
to catecholamines, and at the same time prevented
hypomagnesemia. Maintenance of normal magnesium stores
has been shown to be a critical determinant in protein synthesis
and accordingly, nitrogen retention and synthesis of protoplasm
will occur at reduced rates in patients who are magnesium-
depleted [331.
Phosphorus deficiency and hypophosphatemia. Hypophos-
phatemia and phosphorus deficiency are common and impor-
tant complications of TPN. Similar to those deficiency states
described previously, phosphorus deficiency may exist in the
absence of hypophosphatemia [34]. For example, it is known
that in chronic acidosis, intracellular phosphate stores may be
decreased but hypophosphatemia does not always occur. A
good example of this phenomenon is untreated diabetic
ketoacidosis [35]. It is noteworthy that many chronic alcoholics
are severely phosphorus deficient. Nevertheless, they may not
become hypophosphatemic until the inorganic phosphate in
their extracellular fluid is driven into their cells by means of
either respiratory alkalosis or the anabolic response that occurs
following administration of either amino acids or glucose [361.
Ethanol administered chronically to dogs in intoxicating quanti-
ties results in a decrease of muscle phosphorus content to a
level quantitatively similar to that observed in alcoholic patients
[37]. Even though muscle becomes phosphorus deficient, serum
phosphorus concentration usually remains normal. The mecha-
nism whereby ethanol causes muscle cells to lose phosphorus
has not been elucidated.
Any condition that lowers intracellular pH will simulta-
neously reduce the activity of phosphofructokinase [38]. This
results in decreased phosphorylation, liberation of free phos-
phate ions into the extracellular fluid and excretion of phos-
phate into the urine. A sudden correction of acidosis, or
alternatively, a sudden appearance of the anabolic state will
increase phosphorylation and consumption of extracellular
phosphate so that hypophosphatemia appears [39].
Substantial weight loss as the result of poor food intake does
not ordinarily cause a marked reduction in the total quantity of
phosphorus in muscle tissue if phosphorus content is indexed in
terms of tissue protein [40]. Under such conditions, while
cellular composition measurements might show slight eleva-
tions of sodium, chloride and water content and perhaps slight
decrements of phosphorus and potassium content, severe dis-
turbances are usually not seen. It seems as if cells simply
undergo atrophy and in the process manage to maintain a fairly
normal composition of elements. When such a patient is begun
on TPN, provided their cells are capable of an anabolic re-
sponse, rebuilding of protoplasm will begin. If all nutrients are
provided in ideal quantities, derangements of cellular composi-
tion and plasma composition will usually not occur [41]. On the
other hand, if phosphorus is relatively deficient, phosphorus
deficiency and hypophosphatemia will slowly appear [42]. A
person might be given appropriate quantities of essential amino
acids, calories in the form of both glucose and fat, vitamins,
trace minerals and all elements except, for example, one third
the required amount of phosphorus. As protoplasm is synthe-
sized with inadequate supplies of phosphorus, phosphorus will
virtually disappear from the urine, serum phosphorus will fall
and frank symptoms of hypophosphatemia and phosphorus
depletion will appear in perhaps 1 to 3 weeks. Under such
conditions, the most prominent manifestations of phosphorus
deficiency may be related to central nervous system dysfunc-
tion [43]. Various observers have described irritability, appre-
hension, muscular weakness, numbness, parathesias, dy-
sarthria, dysphagia, inability to swallow secretions, anisocoria,
unreactive dilated pupils, nystagmus, diplopia, patchy visual
field defects in color perception, ptosis, confusion, obtunda-
tion, ballismus, convulsive seizures, coma, and death [43—53].
Because such patients may be profoundly depleted of phospho-
rus, red cell contents of 2,3-diphosphoglycerate (2,3-DPG) and
ATP may be severely depressed [43]. Since both of these
compounds promote the release of oxygen from hemoglobin,
tissue hypoxia is thought to occur and is held responsible for a
great deal of the central nervous system manifestations. Thus,
Travis et al [43] showed that under such conditions, elec-
troencephalographic abnormalities could be related to the de-
pression of red cell 2,3-DPG. The abnormally low 2,3-DPG and
central nervous system dysfunction responded favorably to
phosphate replacement and correction of hypophosphatemia.
Clearly, such symptoms do not appear in patients undergoing
TPN who are not allowed to become phosphorus depleted and
hypophosphatemic. Nevertheless, it seems possible that tissue
hypoxia is not the only abnormality in these patients since at the
prevailing levels of serum phosphorus concentration (below 0.5
to 1.0 mg/dl), it is quite likely that tissue phosphorylation and
utilization of glucose by the brain would be markedly impaired.
Studies to examine the latter possibility have not yet been
performed.
Muscle cell dysfunction and rhabdomyolysis may also occur
in patients who become severely phosphorus depleted and
hypophosphatemic [34, 40, 54]. However, the incidence of this
complication in the setting of TPN has proven to be rare. Most
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cases of hypophosphatemic rhabdomyolysis have occurred in
patients with alcoholism who are severely phosphorus deficient
before hypophosphatemia is induced by other means [34, 541.
Clinical observations [541 and experimental studies [40] suggest
that rhabdomyolysis does not occur with hypophosphatemia
unless muscle cell injury pre-exists. It was shown that phos-
phorus deficiency in the absence of hypophosphatemia induced
a subclinical biochemical injury of the muscle cells [551. If acute
hypophosphatemia was then induced by hyperalimentation,
frank rhabdomyolysis followed [40]. Provision of phosphorus in
adequate quantities to prevent acute hypophosphatemia under
such conditions prevents rhabdomyolysis. In contrast, if a dog
is underfed with an otherwise balanced diet so that derange-
ments of cellular composition do not occur, TPN-induced
hypophosphatemia does not appear to cause injury to muscle
cells [56]. Such observations appear to bear relevance to
several clinical observations. First, acute rhabdomyolysis is
exceptionally rare in patients who have simply lost weight
because of decreased food intake although hypophosphatemia
might appear over the course of days to weeks. In such
patients, muscle phosphorus content was probably normal
before initiation of TPN. Similarly, acute rhabdomyolysis is
exceptionally rare in patients recovering from diabetic
ketoacidosis although they often become hypophosphatemic.
Studies have shown that the great majority of patients treated
for diabetic ketoacidosis are not phosphorus deficient [39].
Indeed, since diabetic ketoacidosis usually develops over a
period of a few days, these patients have not had time to
become significantly phosphorus deficient. The induction of
acute hypophosphatemia by insulin therapy and correction of
metabolic acidosis causes hypophosphatemia but in the absence
of pre-existent muscle cell injury, it seldom results in significant
rhabdomyolysis.
A number of clinical reports have described patients treated
with TPN who have developed acute hypophosphatemia associ-
ated with respiratory failure [46, 48, 49, 51—53, 57—59]. A
number of these patients have become seriously ill from respira-
tory acidosis and hypoxia. Most were desperately ill and in
intensive care unit settings; some were also receiving large
amounts of glucose or amino acids intravenously. Some of the
patients demonstrated abnormalities of central nervous system
function or peripheral neuropathy, profound weakness, and
muscle paralysis before the appearance of diaphragm failure.
Although ascending paralysis may suggest the Guillain-Barré
syndrome, the cerebrospinal fluid is usually normal.
Nearly all patients who have developed acute respiratory
failure during TPN have had pre-existing conditions that would
be expected to cause abnormalities of muscle cell ion transpOrt
and element composition. Reported instances of this interesting
phenomenon have occurred in patients with chronic intestinal
fistulae, malabsorption syndrome, Crohn disease, ulcerative
colitis, small bowel resection, exocrine pancreatic insuffi-
ciency, chronic alcoholism associated with malnutrition, and
gastrointestinal cancer. In each instance, serum phosphorus
concentrations have been less than 1.0 mg/dl. In some cases,
the patients were also hypokalemic. However, as in the report
of Newman, Neff, and Ziporin [57, 58], respiratory failure
persisted despite the correction of hypokalemia, apparently
responding to subsequent administration of phosphate salts and
correction of hypophosphatemia. Experimental studies on
phosphorus deficient dogs have also shown diminished dia-
phragm function as a result of muscular weakness [60].
The incidence of rhabdomyolysis in patients with respiratory
failure and muscular paralysis is difficult to ascertain since
muscle enzyme data are missing from nearly all reports. In
agreement with the cases described by Newman, Neff, and
Ziporin [57, 58] in which CPK values were normal,
rhabdomyolysis in this setting, I suspect, is usually absent or
mild. This speculation is based on the fact that serum phospho-
rus in such patients remains profoundly depressed day after day
and does not follow the usual course of spontaneous correction
as ordinarily seen in rhabdomyolysis. That serum phosphorus
may be within normal limits or even elevated in the presence of
rhabdomyolysis induced by phosphorus depletion and
hypophosphatemia has been recognized in both human [54] and
animal [40] studies. In such instances, the initial hypophos-
phatemia is often missed, and it is assumed that the residual
phosphorus content of skeletal muscle is released in sufficient
quantities to correct the pre-existent hypophosphatemia. In
fact, in our previously reported clinical studies [54], the serum
phosphorus concentration was higher and the muscle phospho-
rus content lower in those patients with the greatest clinical
degree of rhabdomyolysis. The "masking" of phosphorus de-
ficiency as the cause of muscle injury in such instances might
also explain the report by Stewart and Hensley [61], who
described acute rhabdomyolysis during the course of TPN in a
patient with long standing celiac disease and esophageal carci-
noma.
It should be kept in mind that TPN-associated respiratory
failure is not always the result of hypophosphatemia. Covelli et
al [62] described three patients who developed respiratory
acidosis during the course of TPN that was not apparently
associated with hypophosphatemia or other recognizable ele-
ment disturbance. In these patients, ventilatory capacity was
not sufficient to remove carbon dioxide produced by metabo-
lism of nutrients provided in the TPN solutions. Either increas-
ing the volume of ventilation or if that is not possible, reducing
the total amount of calories provided would reduce the Pco2
and improve the carbon dioxide-induced narcosis and acidosis
[63]. Although most patients are capable of increasing their
ventilatory rate to effect removal of carbon dioxide produced by
metabolism, it is well known that patients who are debilitated or
starved show depression of the hypoxic ventilatory response
[64, 65].
Acid-base disorders. A variety of acid-base derangements
may be seen in patients treated by TPN. In a number of these
instances, the particular acid-base disturbance is the result of
the patient's primary disease. For example, patients with
bacteremia and sepsis may develop severe respiratory alkalosis
as a result of hyperventilation [66]. Indeed, the appearance of
respiratory alkalosis with its characteristic depression of cer-
ebral blood flow [67] and resulting mental confusion may be one
of the first clues that sepsis exists.
Although metabolic alkalosis most commonly results from
potassium deficiency or loss of gastric contents due to vomiting
or aspiration, one should realize that it may also appear rather
suddenly in patients who receive glucose following a period of
starvation, so-called "refeeding alkalosis" [68]. Several factors
are thought to be responsible for this interesting phenomenon.
They include (1) an increased renal bicarbonate reabsorptive
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capacity which occurs as a direct result of fasting, (2) a further
increment in this parameter subsequent to the ingestion of
glucose, and (3) generation of new bicarbonate as a result of
metabolizing ketone bodies to bicarbonate and excretion of net
acid by the kidney. Studies by Stinebaugh and Schloeder [681
showed that patients were in positive sodium chloride balance
before alkalosis was induced by refeeding, thus excluding
volume depletion or chloride deficiency as a hypothetical cause
for this phenomenon.
Acute metabolic acidosis in patients undergoing TPN may
occur for several reasons, for example, excessive losses of
alkaline secretions from the pancreas or net bicarbonate loss
from diarrhea. Metabolic acidosis with a high anion gap might
also reflect the presence of uremia. Lactic acidosis may be a
cause in patients who have congestive heart failure, hypoxia, or
those who perfuse their peripheral tissues poorly because of
volume depletion. Phosphorus deficiency and hypophospha-
temia may impair renal excretion of acid.
Hyperchloremic metabolic acidosis may occur as a complica-
tion of TPN therapy with synthetic amino acid preparations, but
it has not been observed in patients who receive casein or fibrin
hydrolysates [69]. Studies on infants receiving these prepara-
tions have excluded loss of base from the gastrointestinal tract
or acidification defects by the kidney. Chan [701 measured the
basal endogenous acid balance in infants receiving 20% glucose
and compared these to acid production and excretion during
infusions of synthetic amino acids and casein hydrolysate. Net
acid production tended to be higher in those infants receiving
the synthetic amino acid solution. This could not be attributed
to either the pH of the solutions administered or their content of
titratable acidity [71]. Heird et al [69] showed very clearly that
the specific amino acid composition of the solutions prepared
from synthetic amino acids would result in hyperchloremic
metabolic acidosis if the solution contained a disproportionate
quantity of the cationic amino acids histidine, arginine, or
lysine. When metabolized, these amino acids yield net hydro-
gen ion production. Originally, the chloride salts of these amino
acids were used; consequently, the end product of their me-
tabolism would be hydrochloric acid. On the other hand, it was
shown that if the chloride ion was replaced by acetate, meta-
bolic acidosis did not occur. This was explained by the fact that
acetate is metabolized and in the process consumes hydrogen
ion thus avoiding metabolic acidosis. To explain the absence of
metabolic acidosis when either casein or fibrin hydrolysates
were employed to TPN, Heird et al [69] showed that these
solutions contained an excess of amino acids carrying a nega-
tive charge at pH 7.4, for example, glutamate and aspartate, and
uncharacterized anionic peptides, that would not yield exces-
sive hydrogen ions when metabolized.
Severe metabolic acidosis in children treated with TPN for
chronic diarrhea and protein calorie malnutrition has been
associated with phosphorus deficiency [72], representing one of
the most fascinating complications of phosphate depletion.
Acid excretion by the kidney depends on the presence of
phosphate in the urine, ammonia production, and the secretion
of free hydrogen ions by the renal tubule. In this process,
Na2HPO4 is filtered at the glomerulus. One of the sodium ions
is exchanged for a hydrogen ion and the phosphate is excreted
as NaH2O4. This component of hydrogen ion excretion is
measured as titratable acidity. Obviously, in nearly all instances
of TPN-induced hypophosphatemia, urinary phosphate concen-
tration becomes essentially zero, thereby eliminating this mech-
anism of acid excretion. One would surmise that in the absence
of phosphate in the urine, the kidney might increase ammonia
production so as to increase the capacity of hydrogen ion
secretion by formation of ammonium ion (NH4 ) in the renal
tubule. Thus, one would suspect that hydrogen ion concentra-
tion would increase in the tubular cell and that this would
increase ammonia production. However, it is of interest that
cellular pH apparently rises under conditions of phosphate
deficiency. Studies directly measuring intracellular pH with the
DM0 technique [73] in liver and muscle have shown this to be
the case. It is assumed that this also happens in the kidney.
Presumably, in phosphorus deficiency, because of intracellular
alkalosis, total ammonia formation in the kidney decreases.
One then must ask, why is metabolic acidosis not a regular
event in all patients with phosphorus deficiency? Thus, when
two of the major mechanisms to excrete metabolic acid are
impaired, how could a normal pH be maintained?
To answer this question, let us consider the normal response
to phosphorus deficiency. When phosphorus is removed from
the diet, and especially if its depletion is accelerated by inges-
tion of phosphate-binding antacids, even before serum phos-
phorus concentration falls, phosphorus is mobilized from the
skeleton. Some believe that an unidentified humoral substance
is released in response to phosphorus deprivation resulting in
mobilization of bone apatite [74]. Bone apatite is composed of
calcium, carbonate, phosphorus, and water. The immediate
response to phosphorus deprivation is the appearance of
hypercalciuria. In the normal adult, mobilization of bone is
almost never of sufficient magnitude to result in hypercalcemia.
In children, presumably because bone is a more active tissue,
phosphorus deprivation is a well recognized cause of both
hypercalcemia and hypercalcuria. The implication is that apa-
tite and hence calcium is mobilized so rapidly that its rate of
excretion by the kidney is not sufficient to prevent
hypercalcemia. In the adult, hypercalcemia does not ordinarily
occur unless there exists some disease that increases bone
turnover such as hyperparathyroidism, Paget disease, or meta-
static cancer of bone. The explanation for the absence of
metabolic acidosis in phosphorus deficiency is thus related to
the mobilization of carbonate from bone which occurs at a
sufficient rate to exactly titrate the hydrogen ions retained by
the kidney. Experimental studies by Emmett et al [75] on
phosphorus deficient rats show that when an agent such as
colchicine is administered to suppress apatite mobilization,
metabolic acidosis rapidly appears.
Studies by Booth, Tsia, and Morris [76] on vitamin D
deficient chicks suggest that if bone mobilization ordinarily
anticipated when phosphorus deficiency is impaired, then meta-
bolic acidosis may occur. This observation seems to coincide
with the report of Kohaut et al [72] on malnourished children
with diarrhea. Thus, if they had a deficiency state that impaired
mobilization of apatite from bone, carbonate would not become
available to buffer retained metabolic acid. In those studies,
administration of phosphorus lead to a rapid increase of titrat-
able acidity of the urine, ammonia production, and a rapid
resolution of metabolic acidosis. In fact, similar to studies on
experimental animals [751, hydrogen ion excretion by the kid-
ney and/or mobilization of carbonate from bone occurred at a
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sufficiently rapid rate that there was an overshoot" metabolic
alkalosis. Other experimental studies on dogs [73] have re-
ported defective bicarbonate reabsorption by the proximal
tubule in severe phosphorus deficiency. This finding could not
be confirmed [77, 78]. Another study has shown a mild defect in
hydrogen ion secretion and urinary acidification in phosphorus-
deprived rats [79].
The cardiovascular system in starvation, TPN, and
hypophosphatemia
Cardiovascular events are commonly the mode of death for
persons who died as a result of starvation or those who die
during a course of refeeding for starvation. Besides being
abnormally small, the heart in starvation is soft, pale, and
flabby [80]. Likewise, the hearts from prisoners of war who died
during the first week of refeeding showed marked brown
atrophy, scattered collections of lymphocytes, condensations
of nuclei, fatty infiltration, and degeneration of autonomic
ganglia.
The cardiovascular system in starving persons rescued from
prisoner of war camps who died as a result of the refeeding
syndrome" is no different from that seen in patients en-
countered today with anorexia nervosa or other conditions
resulting from longstanding inanition and malnutrition. Consid-
ering the severely limited cardiac reserve, one can easily
predict the calamitous cardiac outcome of administering exces-
sively large volumes of solutions composed of hypertonic
glucose and amino acids [811.
Besides clinical evidence for limited cardiac reserve in
cachectic patients [82], substantial evidence suggests that phos-
phorus deficiency and hypophosphatemia also exert adverse
effects on ventricular contractility. O'Connor, Wheeler, and
Bethune [83] showed improvement in left ventricular perform-
ance in patients following treatment for hypophosphatemia.
Experimental studies by Fuller Ct al [841 clearly showed evi-
dence of depressed myocardial performance in phosphorus-
deficient dogs that improved after repletion. Moreover,
Brautbar et al reported abnormalities in energy production [851
and lipid metabolism in phosphorus deficient rates [861.
Finally, it is well known that hypophosphatemia occurs
during nutrition therapy in patients with anorexia nervosa [87,
88]. Thus, physicians who treat patients with severe malnutri-
tion or anorexia nervosa should be aware that the acute
administration of large quantities of calories and large volumes
of fluids to such patients is an unwise therapeutic decision.
There is no need to hurry. In my view, the ideal method for
administering nutrients to poorly nourished patients, especially
those typified by advanced anorexia nervosa, is to begin slowly,
with perhaps 300 to 400 calories on the first day, and to increase
the total number of calories administered per day gradually
while carefully monitoring the patient, both physically and
chemically, in order to avoid problems with hypervolemia,
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